title: Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
abstract: OBJECTIVE
  To compare response rates and remission and survival times in dogs with lymphoma treated with a continuous, multiagent, doxorubicin-based chemotherapeutic protocol or with a short-term single-agent protocol incorporating doxorubicin.
  
  
  METHODS
  Nonrandomized controlled clinical trial.
  
  
  METHODS
  114 dogs with lymphoma.
  
  
  METHODS
  Dogs were treated with a chemotherapeutic protocol consisting of L-asparaginase, vincristine, cyclophosphamide, doxorubicin, methotrexate, and prednisolone (n=87) or doxorubicin alone (27).
  
  
  RESULTS
  63 of 86 (73%) dogs treated with the multiagent protocol (data on response was unavailable for 1 dog) and 14 of 27 (52%) dogs treated with the single-agent protocol had a complete remission. Dogs with lymphoma classified as substage<or=and dogs with a high BUN concentration at the time of initial diagnosis were significantly less likely to have a complete remission. No significant difference in remission or survival time could be demonstrated between treatment groups. Incidence of hematologic and gastrointestinal tract toxicoses did not differ between treatment groups, with the exception that vomiting was more common among dogs treated with the multiagent protocol.
  
  
  CONCLUSIONS
  In this population of dogs, we were not able to identify any significant difference in remission or survival times between dogs with lymphoma treated with a continuous, multiagent chemotherapeutic protocol and dogs treated with a short-term single-agent protocol involving doxorubicin.
authors.affiliation: Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, 30173 Hannover, Germany.
authors.forename: Daniela
authors.initials: D
authors.lastname: Simon
authors.forename: Sol Naranjo
authors.initials: SN
authors.lastname: Moreno
authors.forename: Johannes
authors.initials: J
authors.lastname: Hirschberger
authors.forename: Andreas
authors.initials: A
authors.lastname: Moritz
authors.forename: Barbara
authors.initials: B
authors.lastname: Kohn
authors.forename: Stephan
authors.initials: S
authors.lastname: Neumann
authors.forename: Konrad
authors.initials: K
authors.lastname: Jurina
authors.forename: Stefan
authors.initials: S
authors.lastname: Scharvogel
authors.forename: Claudia
authors.initials: C
authors.lastname: Schwedes
authors.forename: Manfred
authors.initials: M
authors.lastname: Reinacher
authors.forename: Martin
authors.initials: M
authors.lastname: Beyerbach
authors.forename: Ingo
authors.initials: I
authors.lastname: Nolte
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging / Q000662:veterinary; D012074:Remission Induction; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin